Here, we implicate reactivation of TRIM16 as being partially required for tumor targeting by the combination therapy and suggest TRIM16 reactivation as an area for further investigation for melanoma treatment and a potential strategy for targeting BRAF wild-type and mutant melanomas. This evidence concerns the gene BRAF and neoplasm.